CA1264441A - Galenical retard form - Google Patents

Galenical retard form

Info

Publication number
CA1264441A
CA1264441A CA000483768A CA483768A CA1264441A CA 1264441 A CA1264441 A CA 1264441A CA 000483768 A CA000483768 A CA 000483768A CA 483768 A CA483768 A CA 483768A CA 1264441 A CA1264441 A CA 1264441A
Authority
CA
Canada
Prior art keywords
active agent
matrix
dispersion
dispersion according
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000483768A
Other languages
English (en)
French (fr)
Inventor
Jean-Claude Gfeller
Wolfgang Czarnecki
Hans Peter Bier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of CA1264441A publication Critical patent/CA1264441A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA000483768A 1984-06-14 1985-06-12 Galenical retard form Expired CA1264441A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3422083 1984-06-14
DEP3422083.6 1984-06-14
DE3442566 1984-11-22
DEP3442566.7 1984-11-22

Publications (1)

Publication Number Publication Date
CA1264441A true CA1264441A (en) 1990-01-16

Family

ID=25822108

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000483768A Expired CA1264441A (en) 1984-06-14 1985-06-12 Galenical retard form

Country Status (21)

Country Link
AT (1) AT391806B (enExample)
AU (2) AU587190B2 (enExample)
BE (1) BE902626A (enExample)
CA (1) CA1264441A (enExample)
CY (1) CY1635A (enExample)
DE (1) DE3520184C2 (enExample)
DK (1) DK167649B1 (enExample)
ES (1) ES8702141A1 (enExample)
FR (1) FR2565822B1 (enExample)
GB (3) GB2160100B (enExample)
GR (1) GR851430B (enExample)
HK (1) HK25192A (enExample)
HU (1) HU198844B (enExample)
IE (1) IE58834B1 (enExample)
IL (1) IL75490A0 (enExample)
IT (1) IT1200080B (enExample)
LU (1) LU85946A1 (enExample)
NL (1) NL194389C (enExample)
NZ (1) NZ212390A (enExample)
PT (1) PT80635B (enExample)
SE (1) SE504583C2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
EP0406315B1 (en) * 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
GR1000270B (el) * 1988-09-30 1992-05-12 Alza Corp Μορφη δοσολογιας για θεραπεια καρδιαγγειακων ασθενειων.
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
MX9801835A (es) 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
WO2000076480A2 (en) * 1999-06-11 2000-12-21 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
RU2220715C2 (ru) * 1999-08-04 2004-01-10 Яманоути Фармасьютикал Ко., Лтд. Стабильная пероральная, образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
KR100463496B1 (ko) 1999-09-30 2005-01-06 펜웨스트 파머슈티칼즈 컴파니 고가용성 약물용 서방성 메트리스 시스템
NZ526993A (en) * 2001-02-13 2005-01-28 Astrazeneca Ab Pharmaceutical formulation of a drug substance that has a pH-dependent solubility in water
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (de) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
JP2010511713A (ja) 2006-12-05 2010-04-15 ランデック コーポレイション 薬物送達
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
WO2010022193A2 (en) 2008-08-20 2010-02-25 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (de) * 1967-11-17 1971-03-25 Beiersdorf Ag Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkstoffabgabe in Form von Kapseln
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
DE2549740A1 (de) * 1975-11-17 1977-05-18 Sandoz Ag Neue galenische formen und verfahren zu deren herstellung
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
FI64938C (fi) * 1977-06-20 1984-02-10 Sandoz Ag Foerfarande foer framstaellning av nya terapeutiskt anvaendbara bensoxa- och bensotiadiazolyl-1,4-dihydropyridinderivat
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
WO1980001242A1 (fr) * 1978-12-21 1980-06-26 Sandoz Ag Preparations galeniques
DE2904310A1 (de) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh Formlinge mit retardierter wirkstofffreisetzung und verfahren zu deren herstellung
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung

Also Published As

Publication number Publication date
IE58834B1 (en) 1993-11-17
IT1200080B (it) 1989-01-05
GB8727055D0 (en) 1987-12-23
PT80635A (en) 1985-07-01
SE8502950L (sv) 1985-12-15
IL75490A0 (en) 1985-10-31
HK25192A (en) 1992-04-10
GB2160100A (en) 1985-12-18
DE3520184A1 (de) 1985-12-19
GB2160100B (en) 1989-06-01
GB2196851A (en) 1988-05-11
PT80635B (pt) 1987-10-20
IE851460L (en) 1985-12-14
NL194389C (nl) 2002-03-04
HU198844B (en) 1989-12-28
NZ212390A (en) 1992-02-25
DK167649B1 (da) 1993-12-06
HUT40918A (en) 1987-03-30
SE8502950D0 (sv) 1985-06-13
ES544075A0 (es) 1987-01-01
GB2196851B (en) 1989-06-07
NL8501578A (nl) 1986-01-02
BE902626A (fr) 1985-12-10
DK264785D0 (da) 1985-06-12
IT8548210A0 (it) 1985-06-13
GR851430B (enExample) 1985-11-25
AU587190B2 (en) 1989-08-10
GB2196852A (en) 1988-05-11
FR2565822A1 (fr) 1985-12-20
FR2565822B1 (fr) 1989-02-17
GB8727056D0 (en) 1987-12-23
ATA174885A (de) 1990-06-15
ES8702141A1 (es) 1987-01-01
AU4454389A (en) 1990-03-22
LU85946A1 (fr) 1986-01-24
AT391806B (de) 1990-12-10
CY1635A (en) 1992-11-06
GB8514855D0 (en) 1985-07-17
DK264785A (da) 1985-12-15
NL194389B (nl) 2001-11-01
AU4348685A (en) 1985-12-19
SE504583C2 (sv) 1997-03-10
DE3520184C2 (de) 1997-03-13
GB2196852B (en) 1989-05-17

Similar Documents

Publication Publication Date Title
CA1264441A (en) Galenical retard form
CA1304294C (en) Pharmaceutical preparations with extended release
JP6932746B2 (ja) エンザルタミドの製剤
EP0097523B1 (en) Extended action controlled release compositions
KR101512404B1 (ko) 디하이드로피리딘 칼슘 채널 길항제를 포함하는 향상된 의약 조성물 및 이의 준비 방법
EP3257500A1 (en) Apixaban formulations
US5268182A (en) Sustained-release drug dosage units of terazosin
JP2002517431A (ja) マイクロ浸透圧制御薬物送達システム
EP1833466A1 (en) Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
NZ233954A (en) Sustained release pharmaceutical composition comprising 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridine carboxylic acid isopropyl ester
KR890001501B1 (ko) 조절된 서방성을 지닌 활성제의 고형분산액 제조방벙
CH670201A5 (en) Solid dispersions of water-insol. drugs - comprising coherent crystals of drug in water-soluble matrix
SK11072000A3 (sk) Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami
JPS6110507A (ja) 新規遅効性製剤
US20050215455A1 (en) Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them
MXPA00006574A (en) Method and composition of an oral preparation of itraconazole
SI8710407A (sl) Postopek za pridobivanje trdnega pripravka s podaljšanim sproščanjem aktivne spojine

Legal Events

Date Code Title Description
MKEX Expiry